You are here: Industry Insights > Actelion

News List

Owlstone Medical, Actelion team up for pulmonary hypertension detection pharmatimes
May 20, 2019
Owlstone Medical has announced a strategic partnership with Actelion Pharmaceuticals.
Actelion Receives Complete Response Letter from FDA for OPSUMIT americanpharmaceuticalreview
January 21, 2019
Actelion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for OPSUMIT® (macitentan) in the treatment of ....
NHS England to fund Actelion's Uptravi pharmatimes
January 03, 2019
Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag).
Actelion inks $360M deal to wrap DOJ kickbacks probe fiercepharma
December 10, 2018
An industrywide probe of pharma's charitable contributions has spawned multimillion-dollar kickback settlements, and Actelion is the latest to make a deal with the feds.
Actelion’s Opsumit shows promise in portopulmonary hypertension pharmatimes
September 20, 2018
Actelion has unveiled new data showing that the first ever randomised, controlled clinical trial investigating Opsumit as potential...
PAH patients in England denied access to Actelion’s Uptravi on NHS pharmatimes
July 16, 2018
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Wales backs NHS use of Actelion’s Uptravi for PAH pharmatimes
June 21, 2018
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Actelion Receives FDA Approval of TRACLEER americanpharmaceuticacreview
September 07, 2017
PAH is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected person.
J&J completes acquisition of Actelion cphi-online
June 23, 2017
Actelion will now become part of the Janssen Pharmaceutical Companies of J&J.
Actelion spin-off hit by blow shortly before buyout pharmafile
June 12, 2017
Actelion spin-off hit by blow shortly before buyout

Previous page 1 2 Next page